Imfinzi vs Keytruda
Side-by-side comparison of Imfinzi and Keytruda — mechanism, indications, safety, trials, sponsor, and pricing.
At a glance
| Imfinzi | Keytruda |
|---|
| Generic name | Imfinzi | pembrolizumab |
|---|
| Sponsor | University Medical Center Groningen | Merck & Co. |
|---|
| Drug class | — | Monoclonal antibody; PD-1 inhibitor |
|---|
| Molecular target | Programmed cell death 1 ligand 1 | PD-1 receptor |
|---|
| Modality | Small molecule | Monoclonal antibody |
|---|
| Phase | FDA-approved | FDA-approved |
|---|
| Therapeutic area | Oncology | Oncology |
|---|
| First approval | — | 2014-09-04 |
|---|
Mechanism of action
| Imfinzi | — |
|---|
| Keytruda | Pembrolizumab blocks PD-1 receptor, releasing immune inhibition and enhancing anti-tumor T-cell response. |
|---|
Approved indications
Imfinzi
- Extensive stage primary small cell carcinoma of lung
- Liver cell carcinoma
- Metastatic carcinoma to biliary tract
- Non-small cell lung cancer
- Small cell carcinoma of lung
- Transitional cell carcinoma
Keytruda
- Melanoma
- NSCLC (nonsquamous)
- NSCLC (squamous)
- NSCLC (PD-L1+)
- NSCLC (PD-L1+, post-platinum)
- NSCLC (neoadjuvant)
- NSCLC (adjuvant)
- MPM
Common side effects
Keytruda
- Nausea
- Fatigue
- Anaemia
- Diarrhoea
- Constipation
- Decreased appetite
- Hypothyroidism
- Vomiting
Further reading